Prostate cancer diagnostic method and means
AssigneeAit Austrian Institute of Technology GmbH
InventorsJohana Andrea LUNA, Klemens VIERLINGER, Christa NOEHAMMER, Regina SOLDO, Magdalena GAMPERL, Lisa MILCHRAM, Andreas WEINHÄUSEL
Life of this patent
Estimating the term…
Abstract
A method is provided of diagnosing prostate cancer or the risk of prostate cancer in a patient by detecting antibodies against the following marker proteins or a selection of at least 2 or at least 20% of the marker proteins of any List provided herein in a patient, including the step of detecting antibodies binding the marker proteins in a sample of the patient; and systems and kits for such methods.
Claims15
A method of diagnosing prostate cancer or the risk of prostate cancer in a patient by detecting antibodies against the following marker proteins or a selection of at least 2 or at least 20% of the marker proteins selected from OXA1L, GOLM1, NRXN2, PAPSS1, GNAI2, FTSJD2, CERS1, FNTB, MYO19, ADCK3, SDHA, FAM184A (List 1) in a patient, comprising the step of detecting antibodies binding said marker proteins in a sample of the patient.
The method of diagnosing prostate cancer or the risk of prostate cancer in a patient by detecting antibodies against at least 2 or at least 20% of the marker proteins selected from the markers of any one of List 2, 3, 4 or any combination thereof in a patient, comprising the step of detecting antibodies binding said marker proteins in a sample of the patient.
Dependencies are inferred from the claim text.